vorasidenib
servier
['vorasidenib']
vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 idh-mutant glioma. #braincancer #oncology #nursing #asco23 #glioma 
Capturing the voice of nursing professionals in the oncology news landscape.